October Pharma S.A.E (EGX:OCPH)
244.55
-5.01 (-2.01%)
At close: Sep 14, 2026
October Pharma S.A.E Financials Overview
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Revenue Revenue Growth | 1,462 | 1,228 | 1,012 | 727.37 | 655.04 | 543.4 |
Revenue Growth | 22.51% | 21.39% | 39.08% | 11.04% | 20.54% | 3.88% |
Gross Profit Gross Profit Growth | 620.57 | 523.39 | 496.2 | 352.03 | 323.29 | 251.54 |
Operating Income Operating Income Growth | 379.07 | 320.57 | 307.06 | 199.23 | 195.54 | 145.04 |
Net Income Net Income Growth | 165.09 | 131.26 | 150.4 | 113.73 | 119.79 | 88.26 |
Earnings Per Share EPS Growth | 6.88 | 5.47 | 6.27 | 4.74 | 4.99 | 3.68 |
EPS Growth | 4.39% | -12.72% | 32.24% | -5.06% | 35.73% | 160.91% |
| Fiscal Year | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Egypt Egypt Growth | 1,310 | 1,139 | 933.25 |
Export Export Growth | 151.75 | 89.23 | 78.4 |
Total Total Growth | 1,462 | 1,228 | 1,012 |
| Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Investments Cash & Investments Growth | 68.51 | 52.52 | 45.3 | 6.92 | 16.72 | 1.86 |
Total Debt Total Debt Growth | 425.07 | 552.32 | 323.98 | 322.79 | 74.15 | 248.32 |
Net Cash (Debt) Net Cash Growth | -356.56 | -499.8 | -278.68 | -315.87 | -57.43 | -246.46 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -14.86 | -20.82 | -11.61 | -13.16 | -2.39 | -10.27 |
| Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Cash Flow Operating Cash Flow Growth | 371.22 | 43.24 | 153.29 | -92.33 | 262.13 | 53.3 |
Capital Expenditures CapEx Growth | -15.55 | -53.06 | -35.31 | -92.67 | -19.7 | -5.65 |
Free Cash Flow Free Cash Flow Growth | 355.67 | -9.82 | 117.98 | -185 | 242.43 | 47.65 |
Free Cash Flow Growth | - | - | - | - | 408.80% | -24.17% |
| Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Gross Margin | 42.45% | 42.62% | 49.05% | 48.40% | 49.35% | 46.29% |
Operating Margin | 25.93% | 26.10% | 30.35% | 27.39% | 29.85% | 26.69% |
Pretax Margin | 15.91% | 16.53% | 24.19% | 23.85% | 25.14% | 20.83% |
Profit Margin | 11.29% | 10.69% | 14.87% | 15.63% | 18.29% | 16.24% |
FCF Margin | 24.33% | -0.80% | 11.66% | -25.43% | 37.01% | 8.77% |
| Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 15, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Dividend Per Share Dividend Per Share Growth | 1.250 | - | 1.250 | - | - | 0.750 |
Dividend Per Share Growth | - | - | - | - | - | - |
Dividend Yield | 0.50% | - | 2.56% | - | - | 3.25% |
| Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 15, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
PE Ratio | 35.55 | 9.98 | 7.98 | 10.55 | 8.16 | 6.80 |
P/FCF Ratio | 16.50 | - | 10.17 | - | 4.04 | 12.59 |
PS Ratio | 4.02 | 1.07 | 1.19 | 1.65 | 1.49 | 1.10 |